arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Liquidia Corp

LQDA
$90.18 ▲ +0.73 (+0.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
12
Health
Poor
Bearish
auto_awesome

Analytical Summary

Liquidia Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.8B
Dividend Yield
Revenue Growth 1031.2%
Op. Margin -32.5%
ROIC -90.7%
FCF / Share $-0.47
Trailing P/E
Price / Book 175.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$158.32M
↑ +1031.2%
Net Income Profit after all expenses
$-68.92M
↑ +46.3%
Operating Margin Operating profit as % of sales
-32.5%
↑ +92.3% 7th
FCF / Share Free cash flow per share
$-0.47
↑ +62.8%
Long-Term Debt Long-term obligations
$19.88M
↑ +91.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
4
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters